# A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer

> **NCT04181372** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Guangzhou Medical University** · enrollment: 50 (estimated)

## Conditions studied

- Stage III Non-small-cell Lung Cancer

## Interventions

- **DRUG:** Anlotinib hydrochloride
- **DRUG:** platinum-based chemotherapy medicine

## Key facts

- **NCT ID:** NCT04181372
- **Lead sponsor:** The First Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12
- **Primary completion:** 2021-08-01
- **Final completion:** 2022-08-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2019-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04181372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04181372, "A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04181372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*